

Consumer Update

Jan 2023

Clopidogrel has been shown to increase rosuvastatin exposure in patients

[EDA performs label update to include the following:](#)

Clopidogrel has been shown to increase rosuvastatin exposure in patients by 2-fold (AUC) and 1.3-fold (Cmax) after administration of a 300 mg clopidogrel dose, and by 1.4-fold (AUC) without effect on Cmax after repeated administration of a 75 mg clopidogrel dose.

[Background](#)

Clinical Comment

The dose of rosuvastatin should not exceed 20 mg daily when used concomitantly with clopidogrel

Clopidogrel use

Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease.

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin staying aware as a patient.

Consult your doctor for advice when in doubt.

[References:](#) TGA ([Click here](#))